People · Operator
Named in public records as an officer, director or promoter · active 2014–2014 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fibrogen Inc | — | Pharmaceuticals | Series B | $20.0M | $680.1M | 2014 |
Roberto Pedro Rosenkranz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Roberto Pedro Rosenkranz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James A. Schoeneck | 1 | 3 |
| Thomas B Neff | 1 | 3 |
| Rory B. Riggs | 1 | 2 |
| K. Peony H. Yu | 1 | 1 |
| Jorma Pedro Routti | 1 | 1 |
| Miguel F. Madero | 1 | 1 |
| Toshinari N. Tamura | 1 | 1 |
| Kalevi F. Kurkijarvi | 1 | 1 |
| Julian N. Stern | 1 | 1 |
| Pat B. Cotroneo | 1 | 1 |
| Frank H. Valone | 1 | 1 |
| Thomas F. Kearns | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.